## PFE: Pfizer Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (56% of avg), momentum weakening (-2.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure**
- Source: www.sharewise.com | 20251202T162400 | Bullish | Relevance: 100%
- Pfizer is experiencing growth in its oncology division, driven by a strong portfolio of cancer medicines and the strategic acquisition of Seagen. Despite competitive pressures and declining sales for some older drugs like Ibrance, newer therapies and a robust pipeline are contributing to increased revenues. The company expects to have eight or more blockbuster oncology medicines by 2030, reinforcing oncology as a central driver for its long-term outlook, even as its stock performance lags the industry.

**2. Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance**
- Source: BioSpace | 20251202T110711 | Neutral | Relevance: 100%
- Pfizer Inc. is inviting investors and the public to a webcast conference call on December 16, 2025, to present its full-year 2026 financial guidance. The event will be accessible via their investor relations website, where registration details are provided. A replay of the call will also be available for 90 days following the live event.

**3. Pfizer Inc. (PFE) stock price, news, quote and history**
- Source: Yahoo Finance Singapore | 20251202T005140 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of Pfizer Inc. (PFE) stock, including its current price, historical data, and key financial metrics. It details the company's product offerings, therapeutic areas, and collaboration agreements, alongside performance over various periods and analyst insights. The page also features earnings trends, valuation measures, and tools to compare Pfizer with similar pharmaceutical companies.

**4. Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance**
- Source: Business Wire | 20251201T150137 | Neutral | Relevance: 100%
- Pfizer Inc. is inviting the public and investors to a webcast of a conference call with investment analysts on December 16, 2025, at 8:00 a.m. EST. The purpose of the call is to provide Pfizer's full-year 2026 financial guidance. Details for accessing the webcast and a replay will be available on their investor relations website.

**5. Pfizer Stock (PFE) Today â€“ Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)**
- Source: ts2.tech | 20251203T220241 | Somewhat-Bullish | Relevance: 100%
- Pfizer (NYSE: PFE) stock is currently near post-COVID lows but is reshaping its narrative with a $10 billion Metsera acquisition for obesity drugs, expanding RSV vaccine markets, and a high dividend yield. The article provides a deep dive into Pfizer's current stock price, technical outlook, Q3 2025 earnings, strategic moves, risks, and Wall Street forecasts for 2026, generally rating it a "Hold" with potential upside due to valuation and dividend despite integration and regulatory challenges.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.7B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.5 |
| Current P/E | 8.2 |
| YoY Growth | -3.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.7% to -0.2% (-2.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.21% (CS: 50) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.57
- **Stop Loss:** $24.37 (4.7% risk)
- **Target:** $26.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 791
- **Position Value:** $20,225.87
- **Portfolio %:** 20.23%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*